Genomic classifiers in colon cancer - clinical utility.
Rapid technologic advances are allowing for the development of algorithms to predict both patient prognosis, and possibly, responsiveness to specific therapeutic interventions. Such classifiers may potentially be based on hundreds or thousands of possible factors, including data from genomic, proteomic, pathologic, or other factors. As such, in the absence of careful experimental design, there is considerable potential for an over-optimistic assessment of a classifier's true performance in the clinical setting. Here, I describe a multi-step methodology for the development and assessment of genomic classifiers in the setting of colon cancer. Critical issues include the stability and reproducibility of the assay methodology, appropriate choice of patient population, proper segregation of data into learning and validation cohorts, inclusion of known prognostic and predictive factors (eg, staging), and a critical examination of the most relevant performance characteristics. The need for prospective vs. retrospective confirmation is also discussed.
Sargent
Daniel
D
Division of Biostatistics, Mayo Clinic, Rochester, MN.